3Garofalo A,Valle M,Garcia J,et al.Laparoscopic intraperitoneal hyperthermia chemotherapy for pallimion of debilitating malignant ascites[J].Eur J Surg One,2006,32(6):682-685.
4Knutsen A,Sielaff TD,Greeno E,et al.Staged laparoscopic infusion of hyperthermia intraperitoneal chemotherapy after cytoreductive surgery[J].Gastrointest Surg,2006,10(7):1038-1043.
5Gomez Rubio M,de Cuenca Moron B9Dominguez M.Tumoral markers in liver cirrhosis and hepatocellular carcinma[J].Gastroenterol Hepatol,2005,28(5):308.
6Sari R,Yildirim B,Sevinc A,Bahceci F.The importance of serum and ascites fluid alpha fetoprotein carcinoembryonic antigen CAl 9-9 and CAl 5-3 levels in differential diagnosis of ascitesetiology[J].Hepatogastroenterology,2001,48(42):1616-1621.
7Wang IK,Chuang FR,Lee KF,et al.Tuberculous peritonitis in a haemodialysis patient with elevated serum CA125 and hypocaIcaemia[J].Int I Clin Pract Suppl,2005,(147):56-59.
8Morito K,Nakamura J,Kitajima Y,et al.The value of trefoil factor 3 expression in predicting the longterm outcome and early recurrence of colorectal cancer[J].Int J Oncol,2015,46(2):563-568.
9Nicolini A,Ferrari P,Duffy MJ,et al.Intensive risk adjusted follow-up with the CEA,TPA,CA19-9 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences:effect on survival[J].Arch Surg,2010,145(12):1177-1183.
10Polat E,Duman U,Duman M.Diagnostic value of preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 in colorectal cancer[J].Curr Oncol,2014,21(1):1711-1717.
